Therapeutic Drug Monitoring

The contract between this chapter and the reader.

1. 1. Explain why therapeutic drug monitoring is needed.
2. 2. Describe what and how to monitor — trough, timing, and targets.
3. 3. Explain why target levels decline over time.
4. 4. Interpret a high or low drug level.
5. 5. Recognise intra-patient variability and its meaning.
6. 6. Explain the rationale for immunosuppression minimization.
7. 7. Recognise the risks of over-minimization.
8. 8. Address adherence as part of monitoring.
9. 9. Appraise the limits of trough monitoring and minimization.

A sixty-second reading. Each bullet stands alone.

• Calcineurin and mTOR inhibitors have a narrow therapeutic index and variable pharmacokinetics, so exposure is measured to guide dosing.
• Too high an exposure causes toxicity; too low risks rejection.
• Trough (pre-dose) levels are the standard measure, drawn at steady state before the next dose.
• Target levels are higher early, when rejection risk is greatest, and lower later to limit toxicity.
• A high level suggests toxicity risk and prompts a check for interactions and a dose reduction.
• A low level suggests rejection or non-adherence and prompts a check of adherence, absorption, and interactions.
• A sudden change in level usually reflects a drug interaction, a dosing-time error, or non-adherence.
• High intra-patient variability in levels predicts worse graft outcomes and often signals non-adherence.
• Minimization reduces immunosuppression over time as alloimmune risk falls, to limit cumulative toxicity, infection, and malignancy.
• Over-minimization risks rejection, de novo donor-specific antibody, and graft loss.
• Minimization assumes adherence; non-adherence is a hidden under-immunosuppression.
• Mycophenolate levels are not routinely monitored in most practice.
• Monitoring follows the trend, not a single value, and accounts for interactions and timing.

The medical core. An expert should agree drug monitoring and minimization are fully covered here.

Why it matters at the bedside

The maintenance drugs only work within a window: too much and they poison the kidney and the patient, too little and the graft is rejected. Therapeutic drug monitoring is how we find and hold that window, and minimization is how we narrow the dose to the least the graft needs over time. Both are exercises in giving exactly enough — no more, no less.

Why TDM is needed

• Calcineurin inhibitors and mTOR inhibitors have a narrow therapeutic index and wide, unpredictable pharmacokinetics — the same dose gives very different blood levels in different patients, and in the same patient over time. Dosing blind is therefore unsafe: exposure is measured and the dose titrated to it, keeping the patient above the rejection threshold and below the toxicity threshold.

What and how to monitor

• The standard measure is the trough level (C0) — drawn at steady state, immediately before the next dose. It is a practical surrogate for the true measure of exposure, the area under the curve (AUC), which is impractical to obtain routinely; ciclosporin is sometimes monitored by a two-hour (C2) level instead. mTOR inhibitors are also trough-monitored, while mycophenolate levels are not routinely checked in most practice.

Why targets decline over time

• Targets are not fixed. Because the alloimmune response is strongest early, target levels are highest in the first weeks and months and are deliberately lowered over time as rejection risk falls — trading early protection for later freedom from cumulative toxicity. Higher-immunologic-risk patients are held at higher targets for longer.

Interpreting a high or low level

• A high trough warns of toxicity and prompts a search for a CYP3A4 interaction or a dosing-time error before the dose is reduced. A low trough warns of rejection or non-adherence and prompts a check of adherence, absorption, and enzyme-inducing drugs. A sudden, unexplained change almost always means an interaction, a mistimed sample, or missed doses — not a true pharmacokinetic shift.

Intra-patient variability

• Beyond any single value, the variability of a patient's levels over time carries information: high intra-patient variability predicts worse graft outcomes and is one of the best available markers of non-adherence. A patient whose levels swing unpredictably is flagged for an adherence conversation, not just a dose change.

The rationale for minimization

• As the alloimmune threat recedes with time, the immunosuppression that protects the graft increasingly harms the patient — cumulative nephrotoxicity, infection, malignancy, and metabolic disease. Minimization is the planned reduction of immunosuppression as risk falls: lowering calcineurin-inhibitor targets, withdrawing steroids, and trimming the antimetabolite, to give the least drug the graft still needs.

The risks of over-minimization

• Minimization has a floor. Push it too far and the graft rejects, and — more insidiously — the patient forms de novo donor-specific antibody, the road to chronic antibody-mediated rejection and late graft loss (its own chapter). The art is to reduce immunosuppression toward, but not below, the level the individual graft requires — a level that is not directly knowable, which is why minimization is cautious and monitored.

Adherence

• Adherence is the hidden variable in everything above. Minimization assumes the prescribed drug is actually taken; non-adherence is, in effect, an unplanned and uncontrolled minimization, producing low and variable levels, rejection, and de novo DSA. Because non-adherence is common and consequential, it is addressed directly — through education, simplification, barrier-reduction, and vigilance for the variability that betrays it.

Practical monitoring

• In practice: draw troughs at steady state, before the dose; interpret a level in the context of timing, interactions, and adherence; never chase a single value — follow the trend; and educate the patient relentlessly on consistent timing and never skipping doses. The number is only as good as the conditions under which it was taken.

The evidence and its limits

• The honest caveats: the trough is an imperfect surrogate for true drug exposure, so it can mislead; minimization trials show real reductions in toxicity but at the cost of more rejection and de novo DSA, so how low is safe remains uncertain and individual; and high intra-patient variability robustly predicts worse outcomes. Monitoring and minimization are guided by evidence but practised with judgement.

Five fully-built tables.

Table A — What and how to monitor

Table B — Declining targets over time

Table C — Interpreting the level

Table D — Minimization strategies and risks

Table E — Adherence

Visualise & Map

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Drug-level interpretation / dose-adjustment note

• Drug and level: ___ ; target for phase: ___ ; correctly timed trough? yes/no.
• Interpretation: high (interaction/timing) / low (adherence/absorption/inducer) / variable.
• Likely cause identified: ___ (CYP3A4 drug / missed doses / sampling).
• Action: dose change ___ ; adherence addressed ___ .
• Trend reviewed and follow-up level planned: ___.

Template 2 — Minimization plan / adherence note

• Time since transplant and rejection history: ___.
• Adherence assured (variability low)? yes/no.
• Minimization step: lower CNI target / steroid withdrawal / antimetabolite reduction ___.
• Monitoring for de novo DSA / rejection: ___.
• Adherence support provided: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. The trough is convenient but an imperfect picture of true exposure; how much should you trust a number you know is a surrogate?
2. 2. Minimization has a floor you cannot see until you cross it; how do you reduce immunosuppression without learning the floor's location the hard way?
3. 3. Non-adherence is the hidden minimisation no one prescribed; where does the clinician's duty to detect and address it begin and end?
4. 4. A single out-of-range level invites action, but the trend tells the truth; how do you resist over-reacting to one value?
5. 5. Less drug means less toxicity now but maybe a lost graft later; how do you weigh a visible present harm against an invisible future one?

Nine items, each anchored in this chapter. At least one per objective.